Breaking News

Nobelpharma Signs License Agreement to Use ProBioGen’s Vaccine Production Platform

The cell-based system for vaccine production offers a cost-effective, efficient and flexible alternative to traditional vaccine production.

Author Image

By: Charlie Sternberg

Associate Editor

Nobelpharma has signed a license agreement for the use of ProBioGen’s AGE1.CR.pIX vaccine production platform to develop their lead vaccine.   The signing of the agreement is yet another milestone in a series of fruitful collaborations between Nobelpharma and ProBioGen, among them the successful development of a highly efficient manufacturing process for Nobelpharma’s highly relevant viral vaccine.   The advantages of ProBioGen’s proven cell-based production platform for industrial p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters